Highlights from the 2025 Texas Lung Cancer Meeting

The 2025 Texas Lung Cancer Conference (#TexasLung25) was held from April 10–12 at ACL Live at the Moody Theater in Austin, Texas. This IASLC-endorsed, CE-accredited event brought together over 80 leading national experts and community oncologists to discuss the latest advancements in lung cancer care, including immunotherapy, targeted therapies, and innovative treatment approaches.

The conference featured sessions on early-stage and advanced lung cancer, dynamic monitoring, biomarker-guided treatment decisions, and emerging drug classes such as antibody-drug conjugates. Special sessions were dedicated to less common tumors like small cell lung cancer and mesothelioma, as well as discussions on screening, palliative care, patient advocacy, and healthcare policy updates.

Here is a compilation of notable posts from oncologists who attended the conference:

Dr. Stephen V. Liu, Director of Thoracic Oncology at Georgetown University, shared on X:

“Three years of the TLC conference – TexasLung25 starts tonight!”​

Dr. Chul Kim, Thoracic Medical Oncologist at Georgetown University, expressed on X:

“Another amazing and inspiring opening for TexasLung25!”​

Dr. Estela Rodriguez, Associate Director of Community Outreach at Sylvester Comprehensive Cancer Center, noted on X:

“So great to catch up with Aaron Mansfield from Mayo Clinic, one of the leading mesothelioma researchers in the US.”​

Dr. Narjust Florez, Associate Director of the Cancer Care Equity Program and a Thoracic Medical Oncologist at the Dana-Farber Brigham Cancer Center, posted on LinkedIn:

“Started the morning joining this wonderful panel of women leaders in thoracic oncology at 2025 Texas Lung Conference.

Challenges and super powers.

Mentorship vs sponsorship. Stronger together.”​

Dr. Joshua Reuss, Thoracic Medical Oncologist at Georgetown Lombardi Comprehensive Cancer Center, posted on X:

“Insightful discussion on rare thoracic malignancies – thymoma/thymic carcinoma & mesothelioma at TexasLung25. Challenging malignancies to diagnose and treat, often requiring sub-specialty and multi-d input.”​

Dr. Misty Dawn Shields, Medical Oncologist at Indiana University Health, posted on X:

“Such a wonderful discussion about the role of effective communication, support, & the importance of care partners today with Dr. Eric Singhi on the Lung Cancer Considered at IASLC with host Dr. Narjust Florez.

LIVE at #TexasLung25

Check it out!”​

Dr. Mara Antonoff, Associate Professor of Thoracic and Cardiovascular Surgery at MD Anderson Cancer Center, posted on X:

“Very proud to be fighting lung cancer with the MD Anderson Thoracic crew!”​

Dr. Chinmay Jani, Clinical Fellow of Hematology and Oncology at the University of Miami, posted on X:

“Looking forward to an exciting panel discussion on adjuvant targeted treatments in early-stage lung cancer—chaired by our very own dynamic & energetic.”​

Dr. Kelly Mercier, Diagnostic Regional Medical Lead, Oncology Lung at Daiichi Sankyo, posted on X:

“I always learn something practical and insightful from Christine Lovly. She directed us to the IASLC biomarker testing atlas for a comprehensive description of how testing should be conducted and the nuances of doing this right.”​

Dr. Christian Rolfo, Division Director of Medical Oncology and Associate Director for Early Phase Clinical Trials at The James Comprehensive Cancer Center, posted on X:

“Thanks Drs Stephen V Liu and Tina Cascone for the excellent TexasLung25! Amazing meeting, discussions and great atmosphere! I enjoyed our session on biomarkers testing and MRD with good friends.”​

The 2025 Texas Lung Cancer Conference was more than just a gathering—it was a powerful reminder of what’s possible when brilliant minds come together with a shared purpose. From groundbreaking data to heartfelt conversations on equity and patient care, #TexasLung25 left a lasting impact. If you’re passionate about staying at the forefront of cancer research and care, be sure to follow OncoDaily for more insights, updates, and voices from across the oncology world.